Tividenofusp alfa
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies, including AVLAYAH, have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate AVLAYAH in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue AVLAYAH and immediately initiate appropriate medical treatment, including use of epinephrine.
Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full prescribing information for complete boxed warning. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. ( 5.1 ) Initiate AVLAYAH in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment.
( 5.1 ) If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue AVLAYAH and immediately initiate appropriate medical treatment, including use of epinephrine. ( 5.1 )
Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Dosing in kidney impairment
Obtain hemoglobin levels prior to initiating AVLAYAH, at 3 months after initiation, and periodically thereafter as clinically indicated. Administer appropriate supportive measures for anemia based on clinical judgment. 5.4 Membranous Nephropathy A case of steroid-refractory membranous nephropathy with immune complex deposits in the kidney was reported in an AVLAYAH-treated patient [see Adverse Reactions ] .
Preparation and administration
Prepare this dose
Your numbers for tividenofusp alfa. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Dosage and Administration Modifications and Monitoring In the event of a severe hypersensitivity reaction (e.g., anaphylaxis) or a severe IAR, discontinue AVLAYAH and immediately initiate appropriate medical treatment. Consider the risks and benefits of re-administering AVLAYAH following a severe reaction. If the decision is made to re-administer AVLAYAH, re-evaluate pre-treatment medications, slow the infusion rate, and/or reduce the AVLAYAH dose.
Monitor patients closely upon re-administration of AVLAYAH [see Warnings and Precautions (5.1 , 5.2) ] . In the event of a mild to moderate hypersensitivity reaction or a mild to moderate IAR, temporarily hold the infusion and/or reduce the infusion rate by at least 50% from the current rate, then titrate up to the recommended infusion rate as tolerated (see Table 3 ) [see Warnings and Precautions (5.1 , 5.2) ].
If the dose has been decreased due to an adverse reaction, evaluate when it is appropriate to increase the dose and follow the recommended dose escalation regimen to achieve the maintenance dosage of 15 mg/kg once weekly [see Dosage and Administration ].
Preparation Instructions Prepare AVLAYAH using polypropylene syringes and infusion bags composed of polyvinylchloride (PVC) or polyolefins (PO) such as polyethylene (PE) and polypropylene (PP); infusion sets composed of PVC or PE; and filter membranes composed of polyethersulfone (PES). Use aseptic technique during preparation.
Reconstitute and dilute AVLAYAH in the following manner: Reconstitution Instructions 1) Determine the number of AVLAYAH vials to be reconstituted based on the patient's weight in kg and the recommended dosage [see Dosage and Administration ] . Round the number of vials up to the next whole number. 2) Remove the required number of AVLAYAH vials from the refrigerator and set aside for 15 to 30 minutes to allow vials to reach room temperature 20°C to 25°C (68°F to 77°F).
Do not use an external heat source. 3) Reconstitute each vial with 5.2 mL of Sterile Water for Injection by slowly injecting the diluent onto the inside wall of each vial to avoid foaming. Do not inject forcefully or directly onto the lyophilized powder. 4) Gently swirl each vial to completely dissolve the lyophilized powder.
Do not invert or shake the vial. Each reconstituted vial will yield a concentration of 30 mg/mL of tividenofusp alfa-eknm. 5) Visually inspect the reconstituted solution in the vial(s) for particulate matter and discoloration. The solution should be clear to slightly opalescent and colorless to slightly brown/yellow, and free of visible particles.
Discard the reconstituted AVLAYAH solution if it is discolored, cloudy, or contains visible particulates. Dilution Instructions Dilute the reconstituted AVLAYAH solution with 0.9% Sodium Chloride Injection to a final concentration between 0.6 mg/mL and 15 mg/mL [see Dosage and Administration ] in an infusion bag as follows: 1) Determine the appropriate volume of the infusion bag based on patient weight (see Table 2 ) and determine the volume of reconstituted AVLAYAH solution required for the calculated dose. 2) Prepare the infusion bag: a.
Remove any airspace within the infusion bag. b. Withdraw a volume of 0.9% Sodium Chloride Injection from the infusion bag equivalent to the volume of AVLAYAH to be added. 3) Slowly withdraw the required volume of reconstituted solution from the AVLAYAH vial(s). Discard unused portion after each use; do not administer more than one dose from the vial. 4) Slowly inject AVLAYAH into the infusion bag of 0.9% Sodium Chloride Injection.
Avoid introducing air into the infusion bag. 5) Gently invert the infusion bag to mix the solution. Do not shake. [See table below.] 50 mL, 100 mL, or 250 mL 100 mL or 250 mL 100 kg or greater 100 mL or 250 mL 100 mL or 250 mL 250 mL
Storage Instructions for the Reconstituted and Diluted Solutions Reconstituted Solution Do not shake. Do not freeze. If the reconstituted AVLAYAH vials are not diluted immediately, store at controlled room temperature between 20°C to 25°C (68°F to 77°F) for up to 4 hours. Diluted Solution If the diluted AVLAYAH solution is not used immediately, store refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours.
After removal of the diluted solution from the refrigerator: Completely infuse within 10 hours. Do not store back into the refrigerator. Discard the diluted solution if refrigerated more than 24 hours or if the diluted solution cannot be completely infused within 10 hours after removal from the refrigerator. Do not shake.
Do not freeze.
Administration Instructions 1) Administer AVLAYAH without delay as an intravenous infusion using only infusion sets composed of PVC or PE and filter membranes composed of PES. 2) If the diluted solution was refrigerated, allow solution to equilibrate to room temperature prior to infusion. 3) Use a dedicated infusion line equipped with a sterile, non-pyrogenic, low protein-binding, 0.2 micron, in-line filter to administer AVLAYAH. 4) Infuse AVLAYAH over approximately 4 hours per the recommended infusion rates in Table 3.
Increase the initial infusion rate to the subsequent infusion rate every hour based on patient tolerance. Total infusion time should not exceed 8 hours. 5) In the absence of hypersensitivity reactions and IARs, AVLAYAH infusion rate can be gradually increased to complete the infusion in a minimum infusion duration of 3 hours based on patient tolerance. [See table below.] 6) At the end of the infusion, flush the infusion line with 0.9% Sodium Chloride Injection using the final infusion rate that was used to administer AVLAYAH. 7) Do not infuse AVLAYAH in the same intravenous infusion line with other products.
Home Infusion If a patient reaches and tolerates the maintenance AVLAYAH dosage, the patient may receive home infusion under the supervision of a healthcare provider [see Dosage and Administration (2.1 , 2.7) ] . The decision to have patients move to home infusion should be made after evaluation and recommendation by a healthcare provider.
In case of a missed dose or an IAR, contact a healthcare provider.
| Patient Weight Range | AVLAYAH Dose | ||
|---|---|---|---|
| 3 mg/kg | 7.5 mg/kg | 15 mg/kg | |
| Recommended Total Infusion Volumes a | |||
| a Ensure the final concentration of the diluted AVLAYAH solution is between 0.6 mg/mL and 15 mg/mL. | |||
| 5 kg to less than 10 kg | 25 mL | 25 mL or 50 mL | 25 mL or 50 mL |
| 10 kg to less than 20 kg | 25 mL or 50 mL | 25 mL, 50 mL, or 100 mL | 25 mL, 50 mL, or 100 mL |
| 20 kg to less than 25 kg | 25 mL, 50 mL, or 100 mL | 25 mL, 50 mL, or 100 mL | 25 mL, 50 mL, or 100 mL |
| 25 kg to less than 50 kg | 25 mL, 50 mL, or 100 mL | 25 mL, 50 mL, or 100 mL | 50 mL or 100 mL |
| 50 kg to less than 60 kg | 50 mL or 100 mL | 50 mL or 100 mL | 100 mL |
| 60 kg to less than 100 kg | 50 mL, 100 mL, or 250 mL | 50 mL, 100 mL, or 250 mL | 100 mL or 250 mL |
| 100 kg or greater | 100 mL or 250 mL | 100 mL or 250 mL | 250 mL |
| Total Infusion Volume | Infusion Duration | ||
|---|---|---|---|
| First hour | Second hour | Third hour to completion | |
| Infusion Rate (mL/hour) | |||
| 25 mL | 2.5 mL/hour | 5 mL/hour | 10 mL/hour |
| 50 mL | 5 mL/hour | 10 mL/hour | 20 mL/hour |
| 100 mL | 10 mL/hour | 20 mL/hour | 40 mL/hour |
| 250 mL | 25 mL/hour | 50 mL/hour | 100 mL/hour |
Contraindications
None. None ( 4 )
Safety data
Reported adverse events (FAERS)
Liver injury (LiverTox)
LiverTox has no chapter for tividenofusp alfa. Check the label's hepatic warnings.
Pregnancy and lactation
Pregnancy
8.1 Pregnancy Risk Summary There are no available data on the use of AVLAYAH during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Animal studies to evaluate the potential for embryofetal developmental toxicity and pre- and postnatal developmental toxicity of tividenofusp alfa-eknm have not been conducted. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, and other adverse outcomes. In the U.S.
general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.